Japan To Quadruple Order Of Relenza To Back Up H1N1 Flu Treatments
This article was originally published in PharmAsia News
Executive Summary
Japan is in line to receive four times the amount of GlaxoSmithKline's Relenza (zanamivir) it had received a year ago to serve as a treatment against the H1N1 and other strains of influenza. GSK's Japanese subsidiary said it would import the additional doses of the inhalation powder from U.K.-based GSK's plant in France. In addition to the GSK supply, Japan's Chugai Pharmaceutical, a unit of Swiss-based Roche, plans to triple its supply of Tamiflu (oseltamivir), covering up to 12 million people against the flu. (Click here for more - a subscription may be required